Dianthus therapeutics strengthens strategic commercial leadership with appointment of john c. king as chief commercial officer and welcomes sujay kango, a seasoned commercial leader, to board of directors

Mr. king launched the first approved biologic and c5 complement inhibitor into the myasthenia gravis market and helped set the foundation for the multi-billion dollar c5 franchise of alexion

DNTH Ratings Summary

DNTH Quant Ranking